CAR-T therapy for certain relapsed B-blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a personalized CAR-T cell treatment that targets a marker called CD79b in people whose B-blood cancers have come back or not responded to prior treatment. It may help your immune system find and attack cancer cells, but it also requires you to meet safety and health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific type of cancer: B-ALL (B-cell acute lymphoblastic leukemia) or certain B-cell non-Hodgkin lymphomas such as DLBCL, FL, PMBCL, or transformed types
- Your cancer must test positive for the right target (CD79b+), and your diagnosis must be confirmed by pathology (lab tissue testing)
- Your cancer must be relapsed or resistant to standard treatments (or returned after a stem-cell transplant for some types)
- Your general health must be good enough: heart pumping function (LVEF) at least 50%, and you must have no serious uncontrolled infections
- Your blood/organ function must meet thresholds (liver tests, bilirubin, and kidney function) and you should be able to join for at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
This trial tests a new CAR-T cell treatment for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. It aims to see if these immune cells can safely and effectively fight the cancer.
This trial tests a CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatment. The therapy targets specific markers on cancer cells to help your immune system fight the disease.
This trial tests a new CAR-T cell therapy (called ARI-0001) for people with certain blood cancers that have not responded to standard treatments. The treatment uses your own immune cells to fight the cancer.
Hear when a new Relapsed and/or Refractory Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.